Ascendis Pharma A/S’s (ASND) Overweight Rating Reiterated at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports. They currently have a $170.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 32.43% from the stock’s previous close.

A number of other research firms have also recently weighed in on ASND. JPMorgan Chase & Co. lowered their price target on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Jefferies Financial Group increased their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, TD Cowen lifted their target price on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a “buy” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.92.

Ascendis Pharma A/S Stock Up 2.5 %

NASDAQ ASND opened at $128.37 on Monday. The business’s fifty day simple moving average is $133.42 and its 200-day simple moving average is $133.62. The firm has a market cap of $7.78 billion, a PE ratio of -13.46 and a beta of 0.66. Ascendis Pharma A/S has a 52 week low of $86.54 and a 52 week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. Research analysts expect that Ascendis Pharma A/S will post -7.24 EPS for the current year.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its stake in Ascendis Pharma A/S by 4,231.4% in the first quarter. BNP Paribas Financial Markets now owns 75,540 shares of the biotechnology company’s stock worth $11,419,000 after acquiring an additional 73,796 shares during the last quarter. FORA Capital LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter worth $703,000. GSA Capital Partners LLP purchased a new position in Ascendis Pharma A/S in the first quarter valued at $992,000. SG Americas Securities LLC acquired a new stake in Ascendis Pharma A/S in the first quarter valued at $288,000. Finally, ProShare Advisors LLC raised its stake in Ascendis Pharma A/S by 9.9% in the first quarter. ProShare Advisors LLC now owns 4,025 shares of the biotechnology company’s stock valued at $608,000 after buying an additional 361 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.